34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The emerging role and targetability of the TCA cycle in cancer metabolism

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tricarboxylic acid (TCA) cycle is a central route for oxidative phosphorylation in cells, and fulfills their bioenergetic, biosynthetic, and redox balance requirements. Despite early dogma that cancer cells bypass the TCA cycle and primarily utilize aerobic glycolysis, emerging evidence demonstrates that certain cancer cells, especially those with deregulated oncogene and tumor suppressor expression, rely heavily on the TCA cycle for energy production and macromolecule synthesis. As the field progresses, the importance of aberrant TCA cycle function in tumorigenesis and the potentials of applying small molecule inhibitors to perturb the enhanced cycle function for cancer treatment start to evolve. In this review, we summarize current knowledge about the fuels feeding the cycle, effects of oncogenes and tumor suppressors on fuel and cycle usage, common genetic alterations and deregulation of cycle enzymes, and potential therapeutic opportunities for targeting the TCA cycle in cancer cells. With the application of advanced technology and in vivo model organism studies, it is our hope that studies of this previously overlooked biochemical hub will provide fresh insights into cancer metabolism and tumorigenesis, subsequently revealing vulnerabilities for therapeutic interventions in various cancer types.

          Related collections

          Most cited references130

          • Record: found
          • Abstract: found
          • Article: found

          TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis

          The p53 tumor-suppressor protein prevents cancer development through various mechanisms, including the induction of cell-cycle arrest, apoptosis, and the maintenance of genome stability. We have identified a p53-inducible gene named TIGAR (TP53-induced glycolysis and apoptosis regulator). TIGAR expression lowered fructose-2,6-bisphosphate levels in cells, resulting in an inhibition of glycolysis and an overall decrease in intracellular reactive oxygen species (ROS) levels. These functions of TIGAR correlated with an ability to protect cells from ROS-associated apoptosis, and consequently, knockdown of endogenous TIGAR expression sensitized cells to p53-induced death. Expression of TIGAR may therefore modulate the apoptotic response to p53, allowing survival in the face of mild or transient stress signals that may be reversed or repaired. The decrease of intracellular ROS levels in response to TIGAR may also play a role in the ability of p53 to protect from the accumulation of genomic damage.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reflecting on 25 years with MYC.

            Just over 25 years ago, MYC, the human homologue of a retroviral oncogene, was identified. Since that time, MYC research has been intense and the advances impressive. On reflection, it is astonishing how each incremental insight into MYC regulation and function has also had an impact on numerous biological disciplines, including our understanding of molecular oncogenesis in general. Here we chronicle the major advances in our understanding of MYC biology, and peer into the future of MYC research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells

              Because MYC plays a causal role in many human cancers, including those with hypoxic and nutrient-poor tumor microenvironments, we have determined the metabolic responses of a MYC-inducible human Burkitt lymphoma model P493 cell line to aerobic and hypoxic conditions, and to glucose deprivation, using stable isotope-resolved metabolomics. Using [U-(13)C]-glucose as the tracer, both glucose consumption and lactate production were increased by MYC expression and hypoxia. Using [U-(13)C,(15)N]-glutamine as the tracer, glutamine import and metabolism through the TCA cycle persisted under hypoxia, and glutamine contributed significantly to citrate carbons. Under glucose deprivation, glutamine-derived fumarate, malate, and citrate were significantly increased. Their (13)C-labeling patterns demonstrate an alternative energy-generating glutaminolysis pathway involving a glucose-independent TCA cycle. The essential role of glutamine metabolism in cell survival and proliferation under hypoxia and glucose deficiency makes them susceptible to the glutaminase inhibitor BPTES and hence could be targeted for cancer therapy. Copyright © 2012 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                huifeng@bu.edu
                Journal
                Protein Cell
                Protein Cell
                Protein & Cell
                Higher Education Press (Beijing )
                1674-800X
                1674-8018
                26 July 2017
                26 July 2017
                February 2018
                : 9
                : 2
                : 216-237
                Affiliations
                [1 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Abramson Family Cancer Research Institute, , University of Pennsylvania, ; Philadelphia, PA 19104-6160 USA
                [2 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Perelman School of Medicine at the University of Pennsylvania, ; Philadelphia, PA 19104 USA
                [3 ]ISNI 0000 0004 0367 5222, GRID grid.475010.7, Departments of Pharmacology and Medicine, The Center for Cancer Research, Section of Hematology and Medical Oncology, , Boston University School of Medicine, ; Boston, MA 02118 USA
                [4 ]ISNI 0000 0004 0367 5222, GRID grid.475010.7, Program in Biomedical Sciences, , Boston University School of Medicine, ; Boston, MA 02118 USA
                Article
                451
                10.1007/s13238-017-0451-1
                5818369
                28748451
                4cd368fc-2ecd-42a3-9033-65b38efc1835
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 3 May 2017
                : 26 June 2017
                Categories
                Review
                Custom metadata
                © HEP and Springer-Verlag GmbH Germany, part of Springer Nature 2018

                glutaminolysis,the tca cycle,cancer metabolism,glycolysis

                Comments

                Comment on this article